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ABSTRACT
Background: Results from studies using medical record data indicate
chronic (>90 days) opioid analgesic use (OAU) is associated with new
depressive episodes (NDE), worsening depression and risk for depression
recurrence. This body of evidence is based on retrospective cohort studies
and medical record data. Limitations of existing research are overcome in a
new prospective cohort study of the opioid-depression relationship.
Methods: Prospective cohort of 1500 adult patients recruited from two
health care systems. Eligible subjects started a new period of OAU and
have 30 to 90 days of OAU at baseline. Diagnostic assessments for
Open Access

psychiatric disorders, structured measures of pain, pain functioning,
opioid use, social support, sleep and impulsivity will be obtained at
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baseline, 6-month and 12-month follow-up. Baseline participants will be
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invited to 12 monthly brief assessments of pain-related functioning,
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depression symptoms and opioid use.
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Conclusions: Although the annual number of opioid prescriptions in the
United States has decreased, over 190 million patients have OAU each year.
If chronic OAU leads to a clinically meaningful affective disorder,
independent of pain, then we need to consider depression an important
adverse effect of chronic OAU and adjust care for chronic pain accordingly.
KEYWORDS: epidemiology; pain; opioids; depression; anxiety; substance
use disorder; sleep; health related quality of life; social support

INTRODUCTION
There is substantial evidence that depression has a fundamental role
in the prescription opioid epidemic [1]. The bi-directional association
between chronic pain and depression is well-documented. Patients with
chronic pain often see pain as the cause of their depression and seek
opioid therapy to reduce both. The bi-directional association between
chronic prescription opioid analgesic use (OAU) and depression has been
suggested by previous observational studies [2–8] and is the foundation
for our prospective cohort study. We report on a protocol that is designed
to confirm this bi-directional link and determine if a bi-directional
pathway is independent of pain severity and pain related functioning,
social support, substance use disorders, comorbid anxiety disorders,
impaired sleep, sleep apnea and impulsivity.
Depression, and common comorbid conditions such as anxiety and
posttraumatic stress disorder, are related to increased likelihood of
patients with pain receiving opioids, receipt of higher opioid doses,
longer duration of opioid use and increased risk for opioid misuse [7,9–
12]. A review of psychopathology in pain [1] suggests that the OAU
epidemic in the United States reflects under-detected and under-treated
mental illness in patients with non-cancer chronic pain. Patients with
depression report greater pain severity and are less likely to experience
pain relief from OAU compared to non-depressed patients [13,14]. The
blunted analgesic response to OAU may explain why depressed patients
with chronic pain are more likely to receive higher morphine equivalent
doses (MED), which in turn increases risk for opioid misuse and abuse,
accidental overdose and death. Depression may be related to greater
OAU in non-cancer pain because patients overuse opioids in an attempt
to reduce anxiety, moderate mood and improve sleep [9].
A number of retrospective cohort studies have found longer, (≥90 days)
opioid analgesic use (OAU) and rapid dose increases are associated with
significantly greater risk of developing new depression episodes (NDE)
[3,5,15–17]. Patients starting opioids vs those without opioid use have an
increased risk for depression recurrence [18] and chronic OAU is associated
with worsening existing depression [4]. These results were independent of
non-cancer pain. There are few existing prospective cohort studies of new
prescription OAU that measured depression as a key outcome. Results from
the Pain and Opioids IN Treatment (POINT) study, a prospective cohort
J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009
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study of new prescription opioid users, revealed that among the 61% of
subjects with depression in their lifetime, 48% had depression onset after
opioid initiation [19]. Those who did develop depression, compared to those
who did not, started opioids at a younger age, had less social support and
more opioid related difficulties [19]. A study of middle-aged and older
patients found no association between longer OAU and new onset
depression, but opioid related negative mood was reported by 21% of those
who dropped out of the study [20]. At 12-month follow-up, those with more
regular, higher dose use had more depression symptoms than those with
minimal or no OAU [20]. Last a 2-year prospective cohort study of stable
long-term opioid users found no risk for depression following dose
escalation, however this study differs from others in that the sample was
not starting a new period of opioid use at baseline and were all stable, longterm users [21].
With few prospective cohort studies, the existing evidence for a bidirectional association between OAU and depression is based on
retrospective medical record data or longitudinal studies without detailed
measures of depression and comorbid psychiatric disorders. It is possible
that OAU worsens depression symptoms or elicits recurrence of psychiatric
disorders present before the start of observed medical record data. Studies
of chronic OAU and NDE in medical record data lack granularity necessary
to conclude that OAU leads to NDE or is better described as leading to a mix
of depression, dysthymia, anhedonia and vital exhaustion.
Therefore, the first aim of the Pathways study is to determine if
factors that precede a new period of OAU, as shown in Figure 1, explain
the association between chronic OAU and new onset depression and
other affective disorder phenotypes. If NDE is explained by OAU alone
and not by pre-existing risk factors, then the opioid epidemic is
generating new cases of depression in a large population of middle-aged
adults. We test whether the OAU-NDE association is moderated by preexisting depression, posttraumatic stress disorder and substance use
disorder (SUD), including opioid use disorder.
The overall goal of the Pathways study is to reveal why some, but not
all patients with chronic OAU, develop NDE. Thus, our second objective
will determine if common consequences and correlates of OAU such as
poor pain-related functioning, impaired sleep, and/or substance use
disorder are related to increased risk of NDE, independent of OAU. This
aim will help generate possible explanations as to what pathways may
exist from OAU to NDE.
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Figure 1. Factors preceding OAU may increase risk for new onset depression.
A major innovation of our study is measuring dysthymia, mania,
anhedonia, vital exhaustion and major depressive episodes to determine
the phenotype most likely to occur following chronic OAU. Subsequently,
we will be able to identify which depression phenotypes and patterns of
comorbidity are most strongly associated with subsequent opioid misuse,
problem use and use disorder. To our knowledge, there are no studies
which have captured this range of affective disorders/syndromes and
this breadth of opioid misuse and abuse/dependence.
The last objective in the Pathways study is to understand if the
patterns of co-developing pain and OAU are associated with course of
depression (stable, worsening, improving). If depression decreases in
patients with increasing, decreasing or stable pain that co-develops with
decreasing OAU, then decreasing OAU exposure, not pain, should be a
means to reduce the burden of persistent depression in non-cancer pain
populations. Monthly data collection will be used to compute trajectories
of depression that can be linked to changes in OAU, function and pain.
This objective expands seminal work by Kroenke et al. [22], which
revealed a reciprocal, longitudinal relationship between depression and
chronic non-cancer pain but did not account for the co-development of
chronic OAU.
MATERIALS AND METHODS
Subjects
Baseline recruitment continues until 1500 subjects are enrolled.
Feasibility of recruiting this sample and conducting repeated follow-up
assessments is enhanced by splitting the target sample between Saint
Louis University’s (SLU) academic medical practice and Henry Ford
Health System (HFHS). Eligible subjects (eligibility described below) will
be identified using health care systems’ electronic health records (EHR).
By using targeted recruitment and with IRB approval of a HIPAA waiver,
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we will be able to measure potential non-response bias by comparing key
EHR data among participants and refusals.
Subjects are eligible if they are 18–70 years of age, free of cancer and
HIV and have started a new period (i.e., no opioid prescriptions in the
past 3 months) of OAU. We recruit patients who have 30 to 90 days of
OAU at baseline. Those with less than 30 days of OAU are not eligible
because there is no evidence for an increased risk for NDE. Our
electronic health record algorithm generates an eligible sample enriched
for chronic (>90 days) opioid users. Prescription OAU includes short and
long-acting

formulations

hydrocodone,

oxycodone,

dihydrocodeine,

and

any

morphine,

dose

of

codeine,

methadone,

hydromorphone,

levorphanol,

tramadol,

fentanyl

patch,

meperidine,

oxymorphone, pentazocine and tapentadol.
At baseline, OAU eligibility criteria are confirmed and subjects
consent and release PHI prior to beginning the survey. All assessments
are administered in RedCap (a programmable internet based survey
system) and either completed by the subject on the internet or by a
telephone interviewer entering answers into RedCap. Data is collected at
baseline, 6-month and 12-month follow-up. Those who complete baseline
are invited to complete 12 monthly, brief surveys which can be
completed by the subject using RedCap or by telephone interview.
All instruments used for study constructs, when they are administered,
and their sources are shown in Table 1. Baseline and 12-month
assessments measure the following constructs: (1) chronic pain, pain
severity, pain related impaired function, pain duration and recency; opioid
medication use and non-opioid pain treatments; (2) DSM criteria lifetime
and past year major depressive episode, dysthymia, mania, opioid use
disorder, heroin use disorder, cocaine/stimulant use disorder and
marijuana use disorder. To limit subject burden, we use shorter
instruments to measure lifetime and current PTSD, generalized anxiety
disorder and current anhedonia and vital exhaustion, alcohol misuse,
smoking and subject report on parental history of depression and
substance use disorder; (3) sleep quality and sleep apnea; (4) social support
and social functioning and (5) sociodemographics. The EHR data will be
used to measure comorbid conditions, use of other medications and any
pharmacological and non-pharmacological treatments provided for pain
and other conditions. The 6-month follow-up is reduced by excluding DSM
assessments. Baseline and 12-month follow-up take between 45–60 min to
complete and the 6-month follow-up will take 30–40 min to complete. Each
monthly assessment includes the PHQ-9, self-reported OAU and pain
related impairment.
We programmed the Semi-structured Assessment for the Genetics of
Alcoholism (SSAGA) [23] diagnostic instrument to obtain DSM-IV
assessments. To our knowledge, this represents the first, web-based, selfadministered diagnostic instrument applied in clinical epidemiology. The
SSAGA has good test-retest reliability (kappa range 0.70–0.90). Comparison
J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009
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of SSAGA derived diagnosis to diagnoses obtained from the Schedule for
Clinical Assessment in Neuropsychiatry (SCAN) revealed sensitivity and
specificity of 88.2 and 82.5, respectively for depression, 80% sensitivity and
95.7% specificity for opioid abuse/dependence, and 73.3% sensitivity and
86.1% specificity for cannabis abuse/dependence [24].
Table 1. Summary of survey instruments.
Recall period/When

Constructs

Instrument/Measure

Chronic Pain,

Brief Pain Inventory-10

Past 30 days/Baseline, 6-

severity,

item

month, 12-month follow-up

Source

measured
[25]

interference,
duration, recency
Pain

PEGS

severity/functioning
Painful conditions

Past week/12 monthly

[26]

surveys
Electronic medical record

Medical record data from 1

(EMR) data: arthritis,

year before baseline through

musculoskeletal, back pain,

12-month follow-up

Not applicable

neuropathy, headache
Opioid Medication

OAU medication names,

Current/Baseline, 6-month,

Study experts

Use

dose, instructions for use,

12-month follow-up

in clinical

how really taken

Also collected in each of the

pain

Self-report prescription

12 monthly surveys

management

opioid use before age 18

and opioid
research
developed
assessment

Non-opioid pain

Interest in psychological trx

Lifetime/Baseline, 6-month,

Exploratory

treatments

Physical therapy

12-month follow-up

single item

Chiropractic care

questions

cannabidiol
co-medications

Medial record data on non-

Medical record data from 1

opioid analgesics,

year before baseline through

Benzodiazepines,

12-month follow-up

corticosteroids, diseasemodifying anti-rheumatic
drugs, sedative hypnotics,
other psychotropics
criptions
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Table 1. Cont.
Constructs

Instrument/Measure

Recall period/When

Source

measured
Opioid misuse

Prescribed opioid

Past 2 weeks and past

[27,28]

difficulties scale (PODS)

year/Baseline, 6-month, 12-

Single item

month follow-up

exploratory

COMM Current Opioid
Misuse Measure (COMM)
Self-report of
buprenorphine for OUD

Past 30 days/Baseline, 6month, 12-month follow-up
Lifetime–Baseline, 6-month,
12-month follow-up

Lifetime and past 12-

SSAGA RedCap

lifetime and past 12 months,

month DSM-4 opioid

date onset and

use disorder

recency/Baseline and 12-

[23]

month follow-up
Lifetime and past

SSAGA RedCap

lifetime and past 12

year DSM-4 major

months, date onset and

depressive episode,

recency/Baseline and 12-

dysthymia and

month follow-up

mania/bipolar
Depression

PHQ-9 current

12 monthly surveys

[29]

Snaith-Hamilton Pleasure

Past few days/Baseline, 6-

[30,31]

Scale (SHAPS)

month, 12-month follow-

symptoms
Anhedonia

up
Vital Exhaustion

Maastricht Vital Exhaustion

Current/ Baseline, 6-

brief form

month and 12-month

[32]

follow-up
Depression

EMR antidepressants,

Medical record data from

treatment

referral to psychotherapy

1 year before baseline

Not applicable

through wave 3
DSM-4 illicit drug

SSAGA RedCap

use disorders

lifetime and past 12

[23]

months, date onset and
recency/Baseline and 12month follow-up

Alcohol misuse

AUDIT-C

Lifetime and

[33]

current/Baseline, 6-month,
12-month follow-up
Smoking

BRFFS

Lifetime and

[34]

current/Baseline, 6-month
and 12-month follow-up
Family history of

Self-report of mother and

SUD and depression

father any SUD and

Lifetime/Baseline

depression
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Table 1. Cont.
Constructs

Instrument/Measure

Recall period/When

Source

measured
Trauma and PTSD

PC-PTSD-5

Lifetime and past 30 days at

[35]

Baseline, past 30 days only at
Baseline, 6-month and 12month follow-up
Anxiety

GAD-7

Past 2 weeks/Baseline, 6-

[36]

month, 12-month follow-up
Sleep
Sleep Apnea

Pittsburgh Sleep Quality

Past month/Baseline, 6-

Index

month, 12-month follow-up

STOP Questionnaire

Current/Baseline, 6-month,

[37]
[38]

12-month follow-up
Social support

PROMIS SF v2.0–Emotional

Current/Baseline, 6-month,

Support 4a–4 item social

12-month follow-up

[39]

support
Chronic health

EMR, ICD-9 and ICD-10

Medical record data from 1

conditions related to

diagnoses for hypertension,

year before baseline through

depression

heart disease, diabetes,

12-month follow-up

Not applicable

hyperlipidemia, obesity
social functioning

PROMIS Ability to

Current/Baseline, 6-month,

participate in social roles

12-month follow-up

[40]

and activities
Discounting

3 item discounting

Current/Baseline, 6-month,

instrument

12-month follow-up

Sociodemographics–age, gender, education,

Current/Baseline, 6-month,

employment, income, marital status

12-month follow-up

[41]

not applicable

Participants are provided a $50 incentive for baseline, 6- and 12month follow-up survey completion and $10 for each of the 12 brief
monthly surveys completed. A $1000 raffle is offered to those who
complete baseline, 6-month follow-up and the first 6 brief monthly
surveys and a second $1000 raffle offered after the 12-month follow-up
for those who complete all assessments. The electronic health record
algorithm identifies eligible subjects on a weekly basis. Recruitment
packets are sent to eligible subjects who are encouraged to use the
internet to complete the survey. Subjects who do not participate after
receiving the recruitment packet are contacted by research staff via
telephone calls. Attempts to recruit continue for 5 weeks after sending
invitations to participate. Beyond 5 weeks, subjects are no longer eligible
because the early phase of the new period of OAU is past. Standard
thank-you and reminder cards are used to enhance retention.
All data is stored with a code number and after data collection is
complete, coded data is sent to SLU for data analysis. The procedures
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described have been approved by the SLU and HFHS Institutional Review
Boards.
Analytic Approach
Prior to analysis, we will first evaluate missingness and non-response
bias. Missingness will be handled with multiple imputation techniques.
We will test for non-participation bias as a function of age, race, gender,
psychiatric and pain diagnoses and analgesic prescription obtained from
the EHR. Analyses will be weighted by stabilized inverse probability of
participation weights [42–49], if weighted and unweighted results do not
differ, then we report results using unweighted data.
If differences are observed by data collection modality, we will use a
dummy variable in all analyses that indicates self-administered vs.
telephone administration. To control for clustering and reduced standard
error related to subjects within the same health care system, we will
apply a Taylor Series linearization variance estimation, which is similar
to

generating

robust

standard

errors

using

sandwich

variance

estimation [50].
Because opioids are prescribed for pain and pain is associated with
depression and other outcomes, we control for confounding by
indication using propensity scores (PS) and inverse probability of
treatment weighting (IPTW) [42–45]. In this instance, we balance
confounding factors across OAU durataion, i.e., OAU ≤ 90 days and OAU >
90 days. We have used this method successfully in prior studies to
balance confounders by OAU duration when studying duration of OAU
and risk of NDE and worsening depression [4,15,18].
To determine if pre-OAU factors account for post-OAU NDE, we will
use the subject reported NDE age onset. The main exposure is defined as
≤90 days vs >90 days OAU that occurs prior to NDE. Pre-OAU effect
modifiers will be measured at baseline. Unweighted and IPTW, modified
Poisson regression models using robust error variances will calculate
relative risk of NDE comparing OAU > 90 vs ≤ 90 days [51]. Separate,
stratified models based on pre-OAU lifetime depression, PTSD, anxiety,
etc. will be calculated to assess relative risk of NDE based on OAU in the
absence/presence of pre-OAU comorbid psychiatric disorders. A nonstratified model will include interaction terms for OAU x pre-OAU
comorbidities to determine if these pre-OAU factors significantly modify
risk of NDE.
To determine whether post-OAU factors are related to increased risk
of NDE independent of OAU, we will select subjects without any
indication of depression from baseline through 12-month follow-up.
Measurements of post-OAU factors like opioid misuse, social support,
pain function, and poor sleep, will be computed from 6-month follow-up
data. OAU duration of ever >90 vs ≤90 days will be computed from
baseline and 6-month follow-up data and will occur prior to post-OAU
factors. Modified Poisson regression models with robust error variances
J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009
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will be used to calculate relative risk of NDE. Separate models for each
post-OAU variable will be computed. First a crude model and then an
adjusted model adding only OAU duration are computed to assess
whether post-OAU variables have an effect independent of OAU duration.
A fully adjusted model will include all post-OAU variables and OAU
duration.
Brief monthly assessments are used to measure patterns of pain and
opioid co-development associated with stable, increasing, decreasing and
no depression symptoms. Monthly measures will be collapsed into 4
quarterly time points by averaging measures such as opioid dose. This
allows for patients to miss a monthly measure while still providing
informative data for 4 time points. Following Wiggins et al. 2015 [52], we
use complementary approaches by first using a person-centered
approach with parallel process latent class growth analysis (PPLCGA)
[53,54] to measure co-development of pain severity/function, OAU dose,
and depression over time. PPLCGA provides information on the extent to
which pain, OAU, and depression change concurrently over time by
classifying individuals to qualitatively different homogenous groups
based on initial levels (intercepts) and changes over time (slopes). Models
will be estimated starting with one class and increasing classes until
model fit and interpretability are maximized. Fit indices include the LoMendell-Rubin likelihood ratio test, Vuong-Lo-Mendell-Rubin, AIC, BIC,
sample size adjusted BIC, entropy and minimum class size of 1%. The
second approach is variable-centered and helps understand the dynamic
interplay of OAU, pain, and depression, in terms of reciprocal
contributions over time. An autoregressive cross-lagged model with OAU
dose, pain, and depression at quarters 1, 2, 3 and 4 will regress each
variable on all other variables at the previous time point [55,56]. These
models assess: (a) an auto-regressive component, or continuity of each
construct; and (b) a cross-lag component, or the relationship of each
variable at each time point with the other variables at the prior time
point. Model fit will be assessed with likelihood ratio chi-square tests,
comparative fit index, root mean square error of approximation and
standardized root mean square residual.
Depression phenotypes and opioid misuse phenotypes are computed
using Latent Class Analysis (LCA) [57]. Separate LCA will be computed
using 12-month follow-up data to classify individuals based on: (1) NDE
symptoms and (2) NDE comorbid with SUD (alcohol, drug, opioid). The
number of classes will be determined based on fit indices, including
sample size adjusted BIC, adjusted AIC, and Lo-Mendell-Rubin likelihood
ratio test as well as interpretability of classes [58]. The relationship of
OAU duration and each latent class profile at 12-month follow-up will be
assessed using separate unweighted and IPTW multinomial logistic
regression (>2 classes identified) or binary logistic regression (2) classes
identified), with the latent class profile as the outcome.

J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009

Journal of Psychiatry and Brain Science

11 of 18

To determine which depression subtypes and comorbidity subtypes in
patients with >90 day OAU are most strongly associated with incident
opioid misuse and opioid use disorder, we will select subjects without
pre-OAU opioid misuse who have >90 days OAU ever in the 12 months
after baseline. Outcomes include: (1) incident opioid misuse and abuse,
defined as the first occurring at either 6-month or 12-month follow-up;
and (2) opioid use disorder defined at 12-month follow-up. Separate
baseline exposures are: (1) depression sub-types; (2) depression with
comorbid SUD; and (3) depression phenotypes such as DSM-4 major
depressive episode vs dysthymia vs bipolar and anhedonia vs. vital
exhaustion. Separate LCA’s on baseline data using MPlus 8.0 will define
latent class profiles for depression sub-types and depression comorbidity
profiles. Covariates occurring in all assessment time points relative to the
outcome of interest will be included in models. Binary logistic regression
analyses will estimate the association of each exposure with each
outcome by calculating separate crude and adjusted models in SAS v9.4.
Limitations
Our design is intended to enroll patients who are starting a new
period of prescription OAU and many patients will have had a prior OAU
episode. Some subjects may be opioid naïve, but the total sample will not
be directly comparable to a cohort of opioid naïve patients. We chose this
approach, in tandem with recruiting subjects with over 30 days of OAU,
to increase the proportion of subjects who will become long-term opioid
users. If we recruited opioid naïve patients, most patients would be short
term users with little risk for adverse outcomes. Our assessment of
depression obtains lifetime and current depression using a diagnostic
interview with dates of onset and recency. We modified the SSAGA
diagnostic interview to allow for self-administration. Thus stem items are
worded for self-administration and it is possible that psychometric
properties could differ from the standard SSAGA.
Social

desirability

could

influence

accuracy

of

self-reported

prescription OAU, however Goesling et al. 2015 [59] obtained an 83%
sensitivity and 94.2% specificity when comparing subject self-reported
prescription OAU to chart abstraction. Recall-bias is a potential limitation
when measuring lifetime events and symptoms. Our recruitment
method, obtaining measures closest to the start of a new period of opioid
use is intended to limit recall bias, but we acknowledge that there is
always a risk of recall-bias in prospective cohort studies.
DISCUSSION
The Pathways study offers an opportunity to observe the relationships
between prescription OAU, pain, depression and comorbidities and
psychosocial factors in a prospective cohort study in which subjects are
starting a new OAU period. An important distinction of our study is that
we are creating a cohort of prescription opioid users and not illicit
J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009
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opioids or heroin users. Our design controls for a history of illicit
substance use disorder when measuring the association between OAU
and depression. To our knowledge there are no similar cohorts in the
United States. The Australian Pain and Opioids IN Treatment (POINT)
study [60,61], praised for its novel longitudinal design [62], shares some
elements of our cohort study and is meant to reveal predictors of OAU
physical and mental health outcomes, including mortality, over 2 years.
POINT study results will likely be a key source in comparing and
contrasting our results; however, our focus on depression distinguishes
Pathways from the POINT study.
A unique component of the Pathways study is that it is beginning
three years after the CDC opioid prescribing guidelines were published
[63]. Since this landmark publication, the number of new opioid
prescriptions dispensed annually has decreased, many health care
systems and State governments have placed limitations on the duration
of opioid prescriptions for new pain patients and the prevalence of
tramadol dispensing has substantially increased. At first this would seem
to reduce our ability to recruit informative subjects, however, we decided
against trying to create a cohort that was characteristic of chronic opioid
use 5 to 10 years ago. By allowing patients starting tramadol into the
cohort and allowing multiple, short duration prescriptions to accumulate
to 60 days of opioid exposure, our sample will enable us to collect data
from patients exposed to current prescribing patterns. Results will be
relevant to contemporary clinical care and with the large increase in
tramadol use, we expect to report some of the first evidence for or
against a relationship between this medication and depression and
opioid misuse phenotypes.
The results from Pathways will impact several significant public
health problems: chronic pain, the opioid epidemic, opioid misuse and
use disorder and depression with and without comorbid psychiatric
disorders. A crucial implication of our research to date is that NDE occurs
in patients adherent to routine prescription OAU, free of opioid misuse
and occurs in mid-life, beyond the usual age onset for depressive
disorders. Our research to date suggests that these patients have no
recent history of depression (i.e., no diagnoses for 2 years). However we
believe the story is more complicated and this proposal will identify preOAU (e.g., prior depression/dythymia) and/or post-OAU (e.g., impaired
sleep, poor physical and social functioning) risk factors for NDE. Results
will provide an empirical basis for patient-provider risk-benefit
discussions. If patients with no previous history of psychopathology are
as vulnerable for OAU-related affective disorder as those about whom
physicians normally have heightened awareness, (e.g., patients with
opioid misuse or history of substance abuse), then clinicians must
highlight this risk before prescribing. If non-OAU risk factors are found,
then a more patient-centered approach that targets high risk patients is
warranted. Starting an antidepressant may be warranted which may
J Psychiatry Brain Sci. 2020;5:e200009. https://doi.org/10.20900/jpbs.20200009
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facilitate OAU tapering [64]. Our research will clarify when and how
depression develops after OAU so that patients and providers can have
informed discussions about reasonable opioid benefits and vulnerability
to NDE.
CONCLUSIONS
Using medical record data from 2000 to 2013, we have found duration
of opioid use is associated with NDE, depression recurrence and
worsening depression [2–4,15,16,18] Our cohort study will reveal
whether this observation is accurate or better described as chronic OAU
leading to anhedonia, vital exhaustion or dysthymia. We will inform safe
opioid prescribing by elucidating those patients most at risk for adverse
mental health outcomes and by identifying the pre-existing mental
health phenotypes most strongly associated with developing opioid
misuse, abuse and dependence. Last, our study will determine if the OAUdepression association is independent of pain related functional
impairment, low social support and impaired sleep. If we find chronic
OAU is significantly associated with NDE, even after controlling for the
host of confounding factors shown in Table 1, then implementing
training to screen for depression repeatedly during opioid pain
management and treating depression to remission should become a
central feature of safe opioid therapy.
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